CY1112311T1 - Ενωσεις πυραζολινης ως ανταγωνιστες υποδοχεα αλατοκορτικοειδους - Google Patents

Ενωσεις πυραζολινης ως ανταγωνιστες υποδοχεα αλατοκορτικοειδους

Info

Publication number
CY1112311T1
CY1112311T1 CY20121100076T CY121100076T CY1112311T1 CY 1112311 T1 CY1112311 T1 CY 1112311T1 CY 20121100076 T CY20121100076 T CY 20121100076T CY 121100076 T CY121100076 T CY 121100076T CY 1112311 T1 CY1112311 T1 CY 1112311T1
Authority
CY
Cyprus
Prior art keywords
compounds
corticide
competitives
pyrazolin
salt
Prior art date
Application number
CY20121100076T
Other languages
English (en)
Inventor
Marvin Jay Meyers
Graciela Barbieri Arhancet
Xiangyang Chen
Susan Landis Hockerman
Scott Allen Long
Matthew William Mahoney
David Bruce Reitz
Joseph Gerace Rico
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of CY1112311T1 publication Critical patent/CY1112311T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Αποκαλύπτονται ενώσεις και φαρμακευτικώς αποδεκτά άλατα των ενώσεων, όπου οι ενώσεις έχουν την σύνταξη του Τύπου Ι: όπου τα R1, R2, R3Α, R3Β, R4, R5, R6, R7, R8 και Χ είναι όπως ορίζονται στην λεπτομερή περιγραφή της εφεύρεσης. Επίσης αποκαλύπτονται αντίστοιχες φαρμακευτικές συνθέσεις, μέθοδοι θεραπείας και ενδιάμεσα.
CY20121100076T 2006-10-31 2012-01-23 Ενωσεις πυραζολινης ως ανταγωνιστες υποδοχεα αλατοκορτικοειδους CY1112311T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86360606P 2006-10-31 2006-10-31
EP07825488A EP2089367B1 (en) 2006-10-31 2007-10-17 Pyrazoline compounds as mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
CY1112311T1 true CY1112311T1 (el) 2015-12-09

Family

ID=39027523

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100076T CY1112311T1 (el) 2006-10-31 2012-01-23 Ενωσεις πυραζολινης ως ανταγωνιστες υποδοχεα αλατοκορτικοειδους

Country Status (40)

Country Link
US (3) US7781428B2 (el)
EP (1) EP2089367B1 (el)
JP (1) JP4977760B2 (el)
KR (1) KR101107800B1 (el)
CN (1) CN101541757A (el)
AP (1) AP2527A (el)
AR (1) AR063529A1 (el)
AT (1) ATE537151T1 (el)
AU (1) AU2007315884B2 (el)
BR (1) BRPI0717937A2 (el)
CA (1) CA2667966C (el)
CL (1) CL2007003154A1 (el)
CO (1) CO6160307A2 (el)
CR (1) CR10725A (el)
CU (1) CU23779B7 (el)
CY (1) CY1112311T1 (el)
DK (1) DK2089367T3 (el)
EA (1) EA016370B1 (el)
ES (1) ES2375877T3 (el)
GE (1) GEP20115239B (el)
GT (1) GT200700096A (el)
HN (1) HN2007000437A (el)
HR (1) HRP20120078T1 (el)
IL (1) IL198241A0 (el)
MA (1) MA30821B1 (el)
MX (1) MX2009004662A (el)
MY (1) MY145795A (el)
NI (1) NI200900071A (el)
NO (1) NO20091741L (el)
NZ (1) NZ575923A (el)
PE (1) PE20081472A1 (el)
PL (1) PL2089367T3 (el)
PT (1) PT2089367E (el)
RS (2) RS20090208A (el)
SI (1) SI2089367T1 (el)
TN (1) TN2009000160A1 (el)
TW (1) TWI357327B (el)
UA (1) UA92670C2 (el)
UY (1) UY30670A1 (el)
WO (1) WO2008053300A1 (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091057A1 (es) 2007-12-19 2009-07-20 Lilly Co Eli Antagonistas del receptor mineralcorticoide y metodos de uso
JP5728487B2 (ja) * 2009-10-29 2015-06-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 三環式ヘテロ環化合物
ES2566934T3 (es) 2010-05-10 2016-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
WO2011141848A1 (en) 2010-05-11 2011-11-17 Pfizer Inc. Morpholine compounds as mineralocorticoid receptor antagonists
WO2011157798A1 (en) 2010-06-16 2011-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for stimulating reepithelialisation during wound healing
CN102372710A (zh) 2010-08-18 2012-03-14 山东轩竹医药科技有限公司 作为盐皮质激素受体拮抗剂的并环类化合物
US10172907B2 (en) 2010-10-05 2019-01-08 Nova Southeastern University Compositions comprising β-arrestin 1 and methods of use thereof for therapeutic modulation of aldosterone levels in heart disease
RS58274B1 (sr) 2014-06-30 2019-03-29 Astrazeneca Ab Benzoksazinon amidi kao modulatori mineralokortikoidnog receptora
JP6835836B2 (ja) 2015-10-13 2021-02-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 脈絡膜血管新生の処置のための方法及び医薬組成物
WO2018019843A1 (en) 2016-07-26 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
KR102482825B1 (ko) 2016-09-02 2022-12-29 브리스톨-마이어스 스큅 컴퍼니 치환된 트리시클릭 헤테로시클릭 화합물
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company OXIME ETHER COMPOUNDS
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
CN109051490B (zh) 2018-09-18 2024-07-23 深圳市鲸仓科技有限公司 可移动式密集存拣装置
WO2021180818A1 (en) 2020-03-11 2021-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
CN113679716B (zh) 2021-10-13 2024-03-26 史大永 溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用
CN114230457B (zh) * 2022-01-04 2023-06-09 中山大学 一类2-亚苄基四氢萘酮衍生物及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1086068A (en) * 1964-09-02 1967-10-04 Ici Ltd Process for the whitening of polymeric materials and nitrogen-containing polycyclic compounds for use therein
BE789948A (fr) * 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
US3816438A (en) * 1972-12-22 1974-06-11 Sandoz Ag 2h(1)-benzothiepino(5,4-c)-pyrazoles and(1)-benzothiopyrano(4,3-c)-pyrazoles
US3843666A (en) * 1973-05-29 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US4866025A (en) * 1988-09-30 1989-09-12 Eastman Kodak Company Thermally-transferable fluorescent diphenylpyrazolines
DK0623122T3 (da) * 1992-01-23 1997-04-21 Pfizer Benzopyran og beslægtede LTB4-antagonister
GB9318691D0 (en) 1993-09-09 1993-10-27 Merck Sharp & Dohme Therapeutic agents
AR006520A1 (es) 1996-03-20 1999-09-08 Astra Pharma Prod Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion.
JP2001501180A (ja) * 1996-09-05 2001-01-30 アストラ・フアーマシユウテイカルズ・リミテツド 新規なアリールピリダジン
JPH10273467A (ja) * 1997-01-29 1998-10-13 Snow Brand Milk Prod Co Ltd 新規テトラロン又はベンゾピラノン誘導体及びその製造方法
IT1292092B1 (it) 1997-06-05 1999-01-25 Geange Ltd Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
DE69918542T2 (de) 1998-04-30 2005-08-18 Abbott Gmbh & Co. Kg Substituierte trizyklische pyrazolderivate mit protein kinase aktivität
US6432974B1 (en) * 2000-02-04 2002-08-13 Wyeth Pyrrolo-isoquinoline and tetra-hydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-HT7 receptor
EP1492487B1 (en) 2002-03-08 2009-11-11 Merck & Co., Inc. Mitotic kinesin inhibitors
US7250442B2 (en) 2002-03-15 2007-07-31 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
NZ550883A (en) 2002-08-02 2008-06-30 Vertex Pharma Pyrazole compositions useful as inhibitors of glycogen synthase kinase-3 (GSK-3)
CA2496295C (en) 2002-09-18 2010-11-23 Michael John Munchhof Novels pyrazole compounds as transforming growth factor (tgf) inhibitors
MXPA05007857A (es) 2003-01-22 2005-10-18 Lilly Co Eli Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
MXPA06007055A (es) * 2003-12-19 2007-01-30 Lilly Co Eli Moduladores del receptor nuclear de hormona esteroide triciclica.
JP2007230869A (ja) 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
WO2006010142A2 (en) 2004-07-14 2006-01-26 Ligand Pharmaceuticals, Inc. Mineralocorticoid receptor modulator compounds, processes for their preparation, and their use
PT1773768T (pt) 2004-07-30 2018-11-30 Exelixis Inc Derivados de pirrol como agentes farmacêuticos
CA2593156C (en) 2005-01-10 2015-05-05 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptors ligands
WO2006077821A1 (ja) 2005-01-19 2006-07-27 Dainippon Sumitomo Pharma Co., Ltd. アルドステロン受容体調節剤としての芳香族スルホン化合物
CA2594662A1 (en) 2005-02-10 2006-08-17 Merck & Co., Inc. Mitotic kinesin inhibitors

Also Published As

Publication number Publication date
DK2089367T3 (da) 2012-02-06
NO20091741L (no) 2009-05-29
MX2009004662A (es) 2009-05-22
CN101541757A (zh) 2009-09-23
MY145795A (en) 2012-04-30
AP2527A (en) 2012-12-06
GEP20115239B (en) 2011-06-10
RS20090208A (en) 2010-06-30
NZ575923A (en) 2011-01-28
TN2009000160A1 (fr) 2010-10-18
EP2089367B1 (en) 2011-12-14
EP2089367A1 (en) 2009-08-19
IL198241A0 (en) 2009-12-24
TW200822924A (en) 2008-06-01
US20120035131A1 (en) 2012-02-09
US7781428B2 (en) 2010-08-24
BRPI0717937A2 (pt) 2013-12-03
TWI357327B (en) 2012-02-01
SI2089367T1 (sl) 2012-02-29
AU2007315884A1 (en) 2008-05-08
CU23779B7 (es) 2012-02-15
EA016370B1 (ru) 2012-04-30
GT200700096A (es) 2010-07-15
HRP20120078T1 (hr) 2012-02-29
JP4977760B2 (ja) 2012-07-18
AU2007315884B2 (en) 2012-10-04
EA200970341A1 (ru) 2009-10-30
KR101107800B1 (ko) 2012-01-25
WO2008053300A1 (en) 2008-05-08
CR10725A (es) 2009-05-12
CU20090058A7 (es) 2011-07-11
PE20081472A1 (es) 2008-10-18
US20100280016A1 (en) 2010-11-04
CO6160307A2 (es) 2010-05-20
ATE537151T1 (de) 2011-12-15
US20080167294A1 (en) 2008-07-10
PT2089367E (pt) 2012-02-01
KR20090060371A (ko) 2009-06-11
CL2007003154A1 (es) 2008-05-09
ES2375877T3 (es) 2012-03-07
AP2009004822A0 (en) 2009-04-30
UA92670C2 (ru) 2010-11-25
NI200900071A (es) 2010-03-08
AR063529A1 (es) 2009-01-28
JP2010508257A (ja) 2010-03-18
CA2667966A1 (en) 2008-05-08
HN2007000437A (es) 2011-01-17
MA30821B1 (fr) 2009-10-01
CA2667966C (en) 2011-08-02
UY30670A1 (es) 2008-05-31
RS52203B (en) 2012-10-31
PL2089367T3 (pl) 2012-04-30

Similar Documents

Publication Publication Date Title
CY1112311T1 (el) Ενωσεις πυραζολινης ως ανταγωνιστες υποδοχεα αλατοκορτικοειδους
CY1122944T1 (el) Ορισμενες αμινο-πυριμιδινες, συνθεσεις αυτων, και μεθοδοι για χρηση αυτων
NO2023022I1 (no) cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
CY1124837T1 (el) Ενωσεις βενζο[β]θειοφαινιου ως αγωνιστες sting
CY1120207T1 (el) Διαδικασιες για τη συνθεση ενωσεων διαρυλοθειοϋδαντοϊνης και διαρυλυδαντοϊνης
CY1123524T1 (el) Υποκατεστημενα χρωμανια και μεθοδος χρησης
CY1118915T1 (el) Αντιβακτηριακα αναλογα αμινογλυκοσιδης
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
CY1119177T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτα και μεθοδοι χρησης αυτων
CY1111739T1 (el) Πυριδινο[3,4-β]πυραζινονες
ECSP067098A (es) Compuestos y metodos para el tratamiento de dislipidemia
CY1118340T1 (el) Αναστολεις κινασης
CY1119407T1 (el) Διαμορφωτες toy lxr
CY1116741T1 (el) Νεοι συνδετες του υποδοχεα των οιστρογονων
CY1110247T1 (el) Παραγωγα βενζοκιναζολινης και η χρηση τους στην θεραπεια των διαταραχων των οστων
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
CY1112886T1 (el) Ανοσοκατασταλτικος παραγοντας ο οποιος περιλαμβανει μια ετεροκυκλικη ενωση ως δραστικο συστατικο
CY1113450T1 (el) Διαμινοπυριμιδινες ως ρ2χ3 και ρ2χ2/3 ανταγωνιστες
CY1117760T1 (el) Συνδυασμος ενωσεων μορφινανης και αντικαταθλιπτικου για την αγωγη του ψευδοπρομηκικου συναισθηματος
CY1114793T1 (el) Παραγωγα αμινοπυραζολιου
CY1112921T1 (el) Ενεργοποιητες γλυκοκινασης πυρρολιδινονης
CY1116150T1 (el) Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842
CY1107851T1 (el) Παραγωγα πυρολλο-πυριδινης και η χρηση τους ως ανταγωνιστων crth2
CY1113639T1 (el) Παραγωγα βενζαμιδιου και ετεροαρενιου
CY1109728T1 (el) Νεα παραγωγα υδαντοϊνης για τη θεραπεια αποφρακτικων νοσηματων της αναπνευστικης οδου